COST-EFFECTIVENESS OF SACUBITRIL/ VALSARTAN IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE CZECH REPUBLIC- ANALYSIS BASED ON PATIENT CHARACTERISTICS FROM RANDOMIZED CLINICAL TRIAL AND LOCAL REGISTRIES

Author(s)

Spinar J1, Klimes J2, Vesela V2, Deschaseaux C3, Haroun R3, Dostal F2, Depta J3
1University Hospital Brno, Brno, Czech Republic, 2Novartis, s.r.o., Prague, Czech Republic, 3Novartis Pharma AG, Basel, Switzerland

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCV91

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×